Guardant Health — Third Quarter 2026 Earnings Summary

Guardant Health reported third-quarter 2026 revenue of $361.0 million, representing a 36% year-over-year increase driven by a 180% surge in screening revenue and a 58% growth in oncology test volume. The company raised its full-year 2026 revenue guidance to a range of $1.36 billion to $1.37 billion, reflecting expectations of 38% to 40% growth compared to 2025. Despite the revenue expansion, the company reported a net loss of $124.4 million for the quarter, while non-GAAP net loss narrowed to $38.8 million. Recent operational milestones include FDA approvals for Guardant360 CDx as a companion diagnostic for breast cancer treatments and the expansion of Shield commercial coverage to over 80% of eligible lives.